trial · primary record
Anitocabtagene Autoleucel
Newly Diagnosed Multiple Myeloma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 750 |
| Primary completion | 2042-03 |
| Primary endpoint | Minimal Residual Disease (MRD)-Negative Complete Response (CR) or Stringent CR (sCR) Rate at 12 Months |
| Registry ID | NCT07903506 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:48.938Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07903506
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.